| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Celularity Inc. Class A Common Stock
$0.8
+0.04 (+4.54%)
Market Cap
23.18 M
EPS
-3.17
P/E Ratio
-
Value Trade
18.01 K
2.93 %
Week
6.63 %
1 Month
-12.49 %
3 Month
-35.94 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.18 M
52 Week Range
0.56 - 4.01
% held by Insiders
44.28 %
% held by Institutions
7.61 %
Enterprise Value
17.93 M
Total Shares
28.96 M
Short %
2.42 %
Float Shares
7.27 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Celularity Inc. Class A Common Stock
137Total events
1Upcoming
39Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Other Regulator Milestonecenplacel-LEx-US Regulatory
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CYNK-001 | relapsed refractory acute myeloid leukemia (R/R AML) | Phase 1 | 2023-04-27 | 50% of patients in one cohort achieved significant clinical responses; two of four patients achieved an objective response at Day 28; one of three patients achieved MRD negativity Read More | Celularity Contact: Paul Graves, Chief Communications Officer Celularity Inc. paul.graves@celularity.com CELULARITY ANNOUNCES CLINICAL DATA ON HUMAN PLACENTAL-DERIVED UNMODIFIED ALLOGENEIC NATURAL KILLER CE Read More | |
CYNK-001 | relapsed refractory acute myeloid leukemia (R/R AML) | Phase 1 | 2023-04-27 | 50% of patients in one cohort achieved significant clinical responses; two of four patients achieved an objective response at Day 28; one of three patients achieved MRD negativity Read More | Celularity Contact: Paul Graves, Chief Communications Officer Celularity Inc. paul.graves@celularity.com CELULARITY ANNOUNCES CLINICAL DATA ON HUMAN PLACENTAL-DERIVED UNMODIFIED ALLOGENEIC NATURAL KILLER CE Read More | |
CYNK-001 | relapsed refractory acute myeloid leukemia (R/R AML) | Phase 1 | 2023-04-27 | 50% of patients in one cohort achieved significant clinical responses; two of four patients achieved an objective response at Day 28; one of three patients achieved MRD negativity Read More | Celularity Contact: Paul Graves, Chief Communications Officer Celularity Inc. paul.graves@celularity.com CELULARITY ANNOUNCES CLINICAL DATA ON HUMAN PLACENTAL-DERIVED UNMODIFIED ALLOGENEIC NATURAL KILLER CE Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CELU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CELU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CELU
Aug 25, 2026▲ +4.5%today
Celularity Provides Update Regarding Nasdaq Listing Compliance
Celularity Inc. has received a notification from Nasdaq regarding non-compliance due to delayed filings of its Quarterly Reports for the periods ending March 31 and June 30, 2026. The company must submit a plan to regain compliance by September 4, 2026. Despite this, trading of its stock continues without immediate effect on its listing status.
Read more →-CELU
Jun 4, 2026Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Celularity Inc. and Fountain Life Management have announced the availability of cenplacel-L, a placental-derived cell therapy, for investigational use in Florida. This follows new legislation that allows licensed physicians to utilize certain unapproved therapies. The initiative aims to create a scalable pathway for regenerative medicine, leveraging Celularity's manufacturing capabilities and clinical-grade products.
Read more →-CELU
Jun 3, 2026Celularity Releases CEO Letter to Shareholders
Celularity Inc. has released a letter from CEO Robert J. Hariri detailing the company's strategic focus on placental-derived cellular therapies, particularly cenplacel-L. The company has streamlined operations and out-licensed its biomaterials business to strengthen its financial position. Despite challenges in the capital markets, there is strong physician interest in cenplacel-L, positioning Celularity for potential growth in the regenerative medicine sector.
Read more →-CELU
Jun 3, 2026Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity Inc. has appointed Rick Gonzalez as Chief Commercial Officer to enhance its global commercial strategy. His experience in biotechnology and medical technology is expected to drive growth for the company's cenplacel-L and Lifebank offerings. The appointment comes as Celularity aims to expand access to its regenerative therapies amid increasing physician interest.
Read more →-CELU
May 29, 2026Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Inc. received a notice from Nasdaq regarding its delayed filing of the Form 10-Q for Q1 2026, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Despite the notice, trading of CELU stock remains unaffected.
Read more →-CELU
May 4, 2026Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Celularity Inc. has filed its Form 10-K for the fiscal year ending December 31, 2025, regaining compliance with Nasdaq's listing requirements. The company has undertaken strategic initiatives, including the out-licensing of its biomaterials portfolio and a reduction in liabilities by about $13 million. Leadership emphasizes a focused approach towards advancing regenerative medicine and creating long-term value.
Read more →-CELU
Apr 21, 2026Celularity Announces Closing of Transaction with NexGel
Celularity Inc. has completed a transaction with NexGel, where NexGel acquired assets related to Celularity's biomaterials portfolio. The deal, valued at $13.3 million, allows Celularity to focus on its therapeutic pipeline while potentially earning additional milestone payments. This transaction also helps Celularity retire significant debt, enhancing its financial position.
Read more →-CELU
Apr 20, 2026Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. received a notice from Nasdaq for not filing its Form 10-K for the fiscal year ending December 31, 2025. The company has 60 days to submit a compliance plan and may receive an extension of up to 180 days to regain compliance. Despite the notice, trading of its stock continues without immediate effect.
Read more →-CELU
Mar 10, 2026▲ +11.2%on this news
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity Inc. has announced a strategic commercialization partnership for its placental-derived biomaterials, expected to generate up to $35 million in payments. The deal allows Celularity to focus on its longevity therapeutics while retaining exclusive manufacturing rights. An organizational realignment will reduce operating expenses and streamline operations, enhancing capital efficiency.
Read more →-CELU
Mar 10, 2026▲ +11.2%on this newsshared move
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy Transaction expected to generate up to $35 million in upfront and milestone payments Celularity re
Celularity Inc. announced a strategic license deal expected to yield up to $35 million in upfront and milestone payments. The agreement allows Celularity to focus on its longevity therapeutics while retaining exclusive rights to manufacture its commercial biomaterials. This move, along with an organizational realignment, aims to improve capital efficiency and streamline operations. The transaction is anticipated to close by April 15, 2026, pending customary conditions.
Read more →-CELU
Feb 10, 2026Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Celularity Inc. announced it has received $12.2 million from the sale of its unused New Jersey net operating losses and research tax credits. This transaction, facilitated by the New Jersey Economic Development Authority, provides the company with non-dilutive capital to enhance liquidity and support its regenerative medicine initiatives. The funds will aid in advancing their cell therapies targeting aging mechanisms.
Read more →-CELU
Dec 29, 2025▼ -10.4%on this news
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Celularity's CEO, Dr. Robert J. Hariri, expressed support for the CMS's withdrawal of skin substitute Local Coverage Determinations (LCDs), which would have affected other companies' products. Despite the withdrawal, Celularity's Biovance® and Biovance 3L remain eligible for Medicare coverage. The new Medicare payment policy for skin substitutes will still apply, ensuring reimbursement at a flat rate.
Read more →-CELU
Dec 26, 2025Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Celularity's CEO, Dr. Robert J. Hariri, commented positively on the Centers for Medicare & Medicaid Services' withdrawal of skin substitute Local Coverage Determinations. This decision, effective immediately, does not affect the eligibility of Celularity's Biovance® and Biovance 3L products for Medicare coverage. The company continues to support its products with substantial real-world evidence demonstrating their effectiveness in treating chronic wounds.
Read more →-CELU
Dec 22, 2025▼ -9%on this newsshared move
Celularity Announces Closing of Financing Transactions
Celularity Inc. has successfully closed financing transactions, raising $10 million in gross proceeds to support its ongoing operations and strategic initiatives. The financing structure includes a senior secured term loan and a secured convertible note, with potential additional funding available. This capital is intended to aid Celularity's focus on leveraging its placental-derived platform to address significant unmet medical needs related to aging and degenerative diseases. The company plans to articulate a comprehensive corporate strategy that aligns scientific capabilities with long-term opportunities in longevity.
Read more →-CELU
Dec 18, 2025Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
Celularity Inc. has announced binding term sheets for financing transactions that could provide up to $12 million to support its strategic initiatives focused on longevity and human performance. The financing includes a senior secured term loan and a secured convertible note, with initial proceeds expected to be $10 million. This investment is seen as a significant step towards aligning the company's operations with its long-term vision.
Read more →-CELU
Oct 30, 2025Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity Inc. has partnered with DefEYE, Inc. to advance regenerative therapies in eye care. This collaboration includes an exclusive license agreement and a significant investment in DefEYE's funding round. DefEYE aims to expand its portfolio of decellularized biologic solutions for eye care, building on previous commercial success. The partnership is expected to enhance both companies' capabilities in the ophthalmic market.
Read more →-CELU
Oct 14, 2025Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Inc. announced the publication of its Phase 2 clinical trial results for PDA-002, a placenta-derived cell therapy for diabetic foot ulcers complicated by peripheral artery disease. The study showed significant safety and efficacy, with a notable percentage of patients achieving complete wound closure. This therapy may address a critical unmet need in wound care, particularly in Florida where new regulations support its use.
Read more →-CELU
Sep 3, 2025Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Celularity Inc. has filed its Form 10-Q quarterly reports for the first and second quarters of 2025, confirming compliance with Nasdaq Listing Rule 5250(c)(1). The company has also retired $32 million in senior secured debt, which alleviates previous financial pressures. Despite facing challenges earlier in the year, Celularity is now positioned to enhance sales growth and advance its product pipeline.
Read more →-CELU
Aug 18, 2025▲ +19.3%on this news
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Celularity Inc. has successfully completed a significant balance sheet restructuring, retiring all $41.6 million in senior secured debt. This was achieved through an Asset Purchase Agreement with Celeniv Pte. Ltd., allowing Celularity to monetize its intellectual property while retaining exclusive rights to use these assets. The restructuring enhances the company's financial position and operational efficiency.
Read more →-CELU
Aug 18, 2025▲ +19.3%on this newsshared move
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RW
Celularity Inc. has successfully completed a major balance sheet restructuring by retiring all $41.6 million in senior secured debt. The company entered into an Asset Purchase Agreement with Celeniv Pte. Ltd. to monetize its intellectual property assets while retaining exclusive rights to those assets via a License Agreement. Additionally, Celularity has established wholly owned subsidiaries to streamline operations across its commercial businesses. This restructuring enhances the company's financial position and operational efficiency.
Read more →-CELU
Jul 9, 2025▲ +12.2%on this news
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Celularity Inc. has partnered with Fountain Life to provide stem cell therapies in Florida, following a new law that allows licensed physicians to administer such treatments without FDA approval. This collaboration aims to enhance patient access to regenerative therapies, leveraging Celularity's ethically sourced stem cell products. Fountain Life's centers are well-positioned to implement these therapies effectively.
Read more →-CELU
Jul 1, 2025Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
Celularity Inc. has praised a new Florida law that allows physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management. The law, effective July 1, 2025, mandates strict safety and ethical standards, ensuring that stem cells are sourced from FDA-registered facilities. Celularity is ready to supply these therapies and collaborate with Florida physicians.
Read more →-CELU
Jun 10, 2025▲ +5.2%on this news
Celularity Announces Chief Financial Officer Transition
Celularity Inc. announced the termination of its Chief Financial Officer, David Beers, effective immediately, without cause. Joseph DosSantos, the Senior Vice President of Finance, has been appointed as the interim CFO while the company searches for a permanent replacement. The company has also engaged CFO Squad to support financial processes during this transition.
Read more →-CELU
Jun 10, 2025Celularity Announces Chief Financial Officer Transition Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period
Celularity Inc. announced the termination of Chief Financial Officer David Beers, effective immediately, although the decision was not related to the company’s financial performance. Joseph DosSantos has been appointed as interim CFO, maintaining his role as Senior Vice President of Finance. To support financial operations during this transition, Celularity retained CFO Squad, a consulting firm, for outsourced accounting and advisory services. The company aims to improve its financial processes while seeking a permanent CFO.
Read more →-CELU
Jun 2, 2025▲ +6.2%on this news
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Celularity Inc. announced the publication of research demonstrating the effectiveness of its tri-layer decellularized amniotic membrane (DDHAM-3L) for ocular surface reconstruction. The study highlights DDHAM-3L's ability to support the growth and maintenance of induced pluripotent stem cell-derived limbal stem cells, offering a scalable solution for treating limbal stem cell deficiency and other ocular disorders. This innovation could transform treatment options in regenerative medicine.
Read more →-CELU
May 9, 2025Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Inc. reported a significant increase in net revenues for the year ending December 31, 2024, totaling $54.2 million, a rise of 138.1% from the previous year. The growth was largely driven by strong sales in wound care applications. The company also noted a substantial decrease in operating expenses, leading to an improved loss from operations. Positive FDA recommendations for new products further bolster the company's outlook for 2025.
Read more →-CELU
May 9, 2025Celularity Announces Full Year 2024 Operating and Financial Results Net revenues for the year ending
Celularity Inc. reported strong operating and financial results for the year ending December 31, 2024, achieving net revenues of $54.2 million, which represents a 138.1% increase compared to the prior year. The growth was driven largely by significant sales in the Biovance product line, revealing strong demand in wound care applications. Operating expenses also decreased significantly due to the absence of prior impairments, improving the company's financial position. However, despite this positive performance, Celularity still faced operational losses, signaling challenges ahead. CEO Dr. Robert Hariri expressed optimism for continued growth in 2025.
Read more →-CELU
Apr 14, 2025Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Celularity Inc. has welcomed the Centers for Medicare & Medicaid Services' decision to delay the effective date of a Medicare Local Coverage Determination for skin substitute products until January 1, 2026. This action is crucial for maintaining access to treatments for diabetic foot ulcers and venous leg ulcers. The delay follows a previous executive order and aims to facilitate necessary payment reforms.
Read more →-CELU
Apr 7, 2025Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Celularity Inc. announced a publication in Frontiers in Immunology discussing the role of aging in cancer and the therapeutic potential of NK cell therapy. The article emphasizes the importance of preserving NK cell function for healthy aging and suggests that CYNK-001 may mitigate age-related immunological decline. The findings could lead to advancements in treatments for conditions like frailty and sarcopenia.
Read more →-CELU
Feb 25, 2025▼ -9.4%on this news· ran to -28% by day 3
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Celularity Inc. has received recommendation letters from the FDA's Tissue Reference Group for its wound care products, Natalin and Acelagraft™, confirming they meet regulatory criteria under section 361 of the PHS Act. These products are designed for treating partial and full thickness acute and chronic wounds. The global market for biological skin substitutes is expected to grow significantly, indicating strong commercial potential for Celularity.
Read more →-CELU
Feb 24, 2025Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
Celularity Inc. has entered a Master Services Collaboration Agreement with BlueSphere Bio, focusing on manufacturing T cell receptor therapies. This partnership highlights Celularity's advanced cGMP manufacturing capabilities and aims to support BlueSphere's development of therapies for Acute Myelogenous Leukemia. The collaboration underscores Celularity's strategy to leverage its infrastructure for revenue generation.
Read more →-CELU
Feb 24, 2025Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company Leverages Celularity World-class Manufacturing Capabilities
Celularity Inc. has entered into a Master Services Collaboration Agreement with BlueSphere Bio, focusing on the manufacturing of specific cell therapy products, including T cell receptor therapies for Acute Myelogenous Leukemia (AML). This partnership highlights Celularity's advanced cGMP manufacturing infrastructure and aims to attract further clients in the evolving cell therapy landscape. The collaboration represents a significant step in generating revenue and enhancing product development capabilities for both companies. BlueSphere anticipates beginning patient dosing for its TCR T cell therapy products in the first half of 2025.
Read more →-CELU
Jan 27, 2025MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
The MASS Coalition has praised President Trump's Freeze Order, which halts the implementation of Medicare Local Coverage Determinations (LCDs) that restrict access to skin substitute products. This order allows for further evaluation and public comment, ensuring that Medicare beneficiaries suffering from diabetic foot ulcers and venous leg ulcers can access necessary treatments. The Coalition believes this action prevents a potential healthcare crisis for diabetic patients.
Read more →-CELU
Dec 6, 2024Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Celularity Inc. reported significant growth in net product sales for the third quarter of 2024, with total net revenues reaching $36.1 million, a 238.6% increase compared to the same period in 2023. The company has successfully filed its Quarterly Report on Form 10-Q, ensuring compliance with Nasdaq requirements. Product sales saw a remarkable increase of 621.1%, reflecting strong demand for its advanced biomaterial products.
Read more →-CELU
Nov 7, 2024▲ +113.1%on this news· ran to +164% by day 3
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Celularity Inc. has raised its expected net sales guidance for 2024 to between $54 million and $60 million, up from prior estimates. The increase is attributed to strong sales of advanced biomaterial products, including a record high in October. The company has also filed its quarterly reports, addressing previous compliance issues with Nasdaq.
Read more →-CELU
Nov 7, 2024▲ +113.1%on this news· ran to +164% by day 3shared move
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidanc
Celularity Inc. has updated its full year 2024 expected net sales guidance, increasing it to a range of $54 million to $60 million from a previous range of $50 million to $56 million. This adjustment follows strong net sales figures through October, which totaled $44.4 million. Notably, October 2024 recorded the highest expected monthly sales in the company's history. The performance is attributed in part to the strong sales of its new Rebound product and an overall growth projection of 180% to 212% for advanced biomaterial products compared to the prior year.
Read more →-CELU
Oct 23, 2024▲ +7.1%on this news· ran to -20% by day 3
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
Celularity Inc. has filed an appeal with the Nasdaq Hearings Panel regarding its non-compliance with listing rules due to delayed quarterly reports. The company seeks an extension to regain compliance, having already submitted its Form 10-Q for March 31, 2024. However, there is no guarantee of success in the appeal process, and the company may face suspension if compliance is not achieved.
Read more →-CELU
Oct 22, 2024Celularity Provides Corporate Update
Celularity Inc. has provided a corporate update highlighting recent advances in their business, particularly in their advanced biomaterial products. The company has successfully filed its 10-K and 10-Q reports, affirming its commitment to comply with Nasdaq listing requirements. Notably, the acquisition of the Rebound product has boosted sales significantly. Celularity is also advancing several new products aimed at addressing aging-associated diseases, with plans to submit regulatory filings for these products in the coming years.
Read more →-CELU
Oct 16, 2024Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound Product from Sequence LifeScience, Inc.
Celularity Inc. has announced the acquisition of the Rebound product from Sequence LifeScience, enhancing its commercial portfolio of placental-derived advanced biomaterial products. This addition is expected to contribute significantly to Celularity's sales in the fourth quarter of 2024, building on previous strong performance with over $24 million in biomaterial sales in the first half of the year. Dr. Robert J. Hariri emphasized the company's optimism about future prospects and its aim to address a broader patient population in wound care and soft tissue repair. The acquisition aligns with Celularity's strategic vision for growth and reinforces its leadership in regenerative medicine.
Read more →-CELU
Sep 5, 2024Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
Celularity Inc. will present at H.C. Wainwright's 26th Annual Global Investment Conference from September 9-11, 2024. CEO Robert J. Hariri is scheduled to speak, and the company will also hold one-on-one investor meetings. Celularity specializes in placental-derived cell therapies and aims to address aging-related diseases.
Read more →-CELU
Aug 28, 2024Celularity Appoints Richard J. Berman to its Board of Directors
Celularity Inc. has appointed Richard J. Berman to its Board of Directors. Berman, a seasoned public company director with over 40 years of experience in finance and mergers, aims to contribute to Celularity's growth strategy. His expertise includes advising on significant merger transactions, which aligns with the company's focus on developing advanced cell therapies.
Read more →-CELU
Aug 28, 2024Celularity Appoints Richard J. Berman to its Board of Directors Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value
Celularity Inc. has appointed Richard J. Berman to its Board of Directors. Berman is a seasoned public company director with over 40 years of experience in venture capital, management, and mergers and acquisitions. His previous roles include significant positions at Goldman Sachs and Bankers Trust Company, along with advising on over $4 billion in M&A deals. The appointment is seen as a move to bolster the company's growth strategy in regenerative medicine, particularly in the development of placental-derived therapies.
Read more →-CELU
Jul 31, 2024▲ +5.4%on this news
Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023
Celularity Inc. reported a 26.7% increase in combined net sales for 2023, totaling $22.8 million. The company anticipates a strong performance in the first half of 2024, with expected sales between $25.8 million and $27.8 million, reflecting a 290% growth compared to the same period in 2023. CEO Robert J. Hariri emphasized the importance of navigating financial challenges while expanding market presence and product offerings.
Read more →-CELU
Jun 3, 2024Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
Celularity Inc. presented promising data on its T-cell therapy platform at the ASCO Annual Meeting. The data highlights the potential of PT-CD16VS, a genetically modified T-cell therapy, to effectively target various hematological and solid tumors when combined with monoclonal antibodies. This approach aims to overcome challenges associated with traditional cell therapies.
Read more →-CELU
May 14, 2024▲ +26%on this news
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity Inc. announced that the Journal for ImmunoTherapy of Cancer published data showcasing the advantages of its placental-derived T-Cell platform for CAR-T therapies. The study found that these T-Cells maintained stemness and showed better persistence and efficacy compared to traditional PBMC-derived CAR-T cells. The findings suggest promising prospects for more effective and safer CAR-T therapies.
Read more →-CELU
Apr 22, 2024Celularity Inc. to Host Investor and Analyst Research & Development Day
Celularity Inc. will host its inaugural Investor and Analyst Research & Development Day on May 21, 2024, in Florham Park, NJ. The event will highlight the company's progress in placental-derived therapies and advanced biomaterials. Key executives will present, and a live webcast will be available for those unable to attend in person.
Read more →-CELU
Apr 18, 2024Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
Celularity Inc. announced that its abstract on decellularized placental biomaterials for tendon injuries was accepted at the ORS Tendon Conference 2024. The study highlights the biomaterials' biomechanical properties and their potential in tendon repair. The global tendon market is projected to grow significantly, and Celularity aims to leverage this opportunity to enhance its regenerative biomaterials business.
Read more →-CELU
Apr 15, 2024Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Celularity Inc. has announced that its net sales for the first quarter of 2024 are exceeding previous expectations, indicating strong market adoption of its advanced biomaterial products. The company plans to implement reductions in SG&A expenses, including executive compensation, to support production expansion. Celularity's advanced biomaterial pipeline includes several commercial and investigational products aimed at addressing significant medical needs.
Read more →-CELU
Apr 8, 2024Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
Celularity Inc. announced it will present promising preclinical data on its NK cell therapies at the ASGCT Annual Meeting. The data suggests that both unmodified and genetically modified NK cells may effectively eliminate senescent cells, which are linked to age-related diseases. This presentation underscores Celularity's commitment to developing innovative treatments targeting degenerative conditions.
Read more →-CELU
Mar 26, 2024Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
Celularity Inc. has received HCPCS Q code approval from the U.S. Centers for Medicare & Medicaid Services for its Biovance® 3L product. This tri-layer allograft is intended for use in treating various types of wounds. The Q code will be effective from April 1, 2024, and is expected to enhance the product's adoption and impact in clinical settings.
Read more →-CELU
Mar 20, 2024Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Celularity Inc. has submitted a request for orphan drug designation from the FDA for its placental-derived cell therapy, PDA-002, aimed at treating Facioscapulohumeral Muscular Dystrophy (FSHD). The company has already received IND clearance and plans to initiate a Phase 1/2 clinical trial in late 2024. FSHD affects approximately 1 in 8,000 people, and there are currently no effective treatments available.
Read more →-CELU
Mar 14, 2024Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
Celularity Inc. announced that its CEO, Dr. Robert Hariri, will present at the ABUNDANCE Summit on March 21, 2024. His presentation will focus on the potential of cellular therapy to combat aging and improve longevity. Dr. Hariri aims to showcase how placental-derived cells can address age-related health issues, positioning Celularity as a leader in regenerative medicine.
Read more →-CELU
Mar 12, 2024▼ -15.3%on this newsshared move
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
Celularity's CEO, Dr. Robert Hariri, will present a keynote address at the SBMT Annual World Congress on March 16, 2024. His talk will focus on the potential of cellular immunotherapy in treating chronic conditions, including cancer and neurodegenerative diseases. Dr. Hariri will also participate in two additional panels, emphasizing the integration of technology in cellular medicine.
Read more →-CELU
Mar 7, 2024▲ +27.7%on this news· ran to +44% by day 1shared move
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
Celularity Inc. announced it will present in vivo data on its PT-CD16VS cell therapy at the AACR Annual Meeting 2024. The data demonstrates significant anti-tumor activity against gastric cancer when combined with trastuzumab. This highlights the potential of Celularity's platform to enhance cancer treatment options and address aging-related health challenges.
Read more →-CELU
Feb 23, 2024▲ +6.1%on this news
Celularity Announces 1-for-10 Reverse Stock Split
Celularity, Inc. has announced a 1-for-10 reverse stock split of its Class A common stock, effective February 28, 2024. This decision, approved by stockholders, aims to increase the share price to meet Nasdaq listing requirements. The company anticipates that this move will enhance investor visibility and support revenue growth in its biomaterial and biobanking sectors.
Read more →-CELU
Feb 14, 2024Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
Celularity Inc. announced that its research on a tri-layer decellularized, dehydrated human amniotic membrane has been accepted for presentation at the 12th World Biomaterials Congress. The study explores its use as a carrier for induced pluripotent stem cell-derived limbal stem cells in treating limbal stem cell deficiency, a significant ocular surface disorder. The findings suggest this approach may improve patient access to treatment.
Read more →-CELU
Feb 12, 2024Description of Business Celularity Inc. ("Celularity") is a cellular and regenerative medicine company developing cryopreservable "off-the-shelf" placental-derived allogeneic cellular therapies and advanced biomaterial p
Celularity Inc. is focused on developing innovative placental-derived cellular therapies and advanced biomaterial products aimed at addressing critical unmet medical needs. The company leverages its proprietary technology platform to utilize the post-partum placenta for various therapeutic applications, particularly in oncology, autoimmune diseases, and aging-related conditions. It also intends to expand its operations into adult cell banking and contract manufacturing services. Despite its advancements, Celularity must navigate typical industry risks, and the commercialization of its drug candidates remains uncertain.
Read more →-CELU
Feb 1, 2024▲ +28.4%on this news· ran to +42% by day 1
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
Celularity Inc. anticipates significant growth in net sales for both the first quarter and full year of 2024, projecting increases of 249% to 287% for its advanced biomaterial products. The company is focusing on expanding its commercial pipeline and preparing for new product launches. CEO Robert J. Hariri expressed optimism about the company's unique business model and growth potential.
Read more →-CELU
Jan 25, 2024▲ +16%on this news
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
Celularity Inc. has successfully closed two financing transactions totaling $21 million, which includes a $6 million private placement and a $15 million amended loan agreement. This capital infusion is expected to strengthen the company's balance sheet and support its growth in cellular medicine and biomaterials. The CEO expressed optimism for the company's future in 2024, highlighting the potential for revenue growth.
Read more →-CELU
Jan 4, 2024▼ -9.3%on this news
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
Celularity Inc. has confirmed a strategic commercialization agreement with BioCellgraft for the manufacture and distribution of advanced biomaterial products in the U.S. dental and oral healthcare markets. This partnership aims to address applications in periodontology, implant dentistry, and oral surgery, which are significant and expanding sectors. The agreement is expected to enhance Celularity's market presence and product reach.
Read more →-CELU
Jan 3, 2024▲ +14.2%on this newsshared move
BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare
BioCellgraft has entered an exclusive commercialization agreement with Celularity to distribute placental-derived biomaterial products for oral healthcare in the U.S. This partnership aims to address various dental needs, including soft tissue augmentation and periodontal applications. The collaboration is expected to leverage both companies' expertise to innovate in the dental market.
Read more →-CELU
Jan 3, 2024Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
Celularity Inc. has announced expected net sales for its biomaterial products and biobanking businesses, projecting $11.4 million to $12.1 million for Q4 2023 and $22.06 million to $22.76 million for the full year 2023. This represents a significant increase compared to the same periods in 2022. The company is optimistic about its growth trajectory and plans to provide further revenue guidance for 2024.
Read more →-CELU
Jan 3, 2024Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 mill
Celularity Inc. announced expectations for substantial net sales and total revenues for both the fourth quarter and full year of 2023. Anticipated sales of biomaterial products and biobanking businesses are projected to be between $11.4 million and $12.1 million for Q4, reflecting a triple-digit growth compared to the same period in 2022. For the full year, the expected sales range is set between $22.06 million and $22.76 million, indicating growth between 22.7% and 26.6% year-over-year. The company’s CEO expressed optimism regarding the growth of their commercial-stage products amidst industry challenges, suggesting future revenue guidance across the business soon.
Read more →-CELU
Nov 24, 2023Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Celularity Inc. has received a notification from Nasdaq regarding its non-compliance due to the late filing of its Form 10-Q for Q3 2023. The company must submit a compliance plan within 60 days and has until May 20, 2024, to implement it. Additionally, Celularity is also not meeting Nasdaq's minimum bid price requirement, with a deadline of March 11, 2024, to rectify this issue.
Read more →-CELU
Oct 24, 2023▼ -8.6%on this news
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification
Celularity Inc. has received classification from the Saudi Food and Drug Authority (SFDA) for its Halal Certified biomaterial products as 'Minimally Manipulated Biological Products.' This classification facilitates the importation of these products into Saudi Arabia, marking a significant step in Celularity's globalization strategy and partnership with Tamer Group for distribution in the region.
Read more →-CELU
Sep 7, 2023Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Inc. has appointed Dr. Geoffrey Shiu Fei Ling to its Board of Directors. Dr. Ling, a veteran in regenerative medicine and a military physician-scientist, is expected to contribute significantly to the company's mission of developing innovative cellular therapies. His extensive background and experience will aid in advancing Celularity's investigational products.
Read more →-CELU
Sep 7, 2023Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular Therapies
Celularity Inc. has appointed Dr. Geoffrey Shiu Fei Ling to its Board of Directors, a move expected to enhance its capabilities in developing cellular therapies. As a recognized leader in regenerative medicine with over 30 years of experience, Dr. Ling brings valuable insights to the company. His background includes significant contributions to military medicine and academic research, promising to advance Celularity's pipeline of therapeutic solutions. The appointment comes alongside the resignation of Andrew von Eschenbach from the board, marking a transition in leadership as the company seeks to innovate in the biotechnology space.
Read more →-CELU
Aug 29, 2023▲ +8%on this news· ran to +26% by day 3
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Celularity Inc. has entered into a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals to support research on targeted allogeneic CAR T-cell therapies. The collaboration aims to enhance the efficacy of therapies against solid tumors and will utilize Celularity's advanced facilities in New Jersey. The financial details of the agreement have not been revealed.
Read more →-CELU
Aug 29, 2023▲ +8%on this news· ran to +26% by day 3shared move
Celularity Investor Contact : Carlos Ramirez, Senior Vice President Celularity Inc. Carlos.ramirez@celularity.com Celularity Media Contact : Factory PR celularity@factorypr.com CELULARITY ANNOUNCES MULTI-YE
Celularity Inc. announced a multi-year research collaboration agreement with Regeneron Pharmaceuticals, focusing on support for allogeneic CAR T-cell therapy research. This collaboration emphasizes Celularity's expertise in cellular therapies and aims to enhance the proliferation and potency of CAR T-cells against solid tumors. The research will be conducted at Celularity's Florham Park, N.J., facility. CEO Robert J. Hariri highlighted the significance of the partnership with a leading innovator in medicines, although financial details were not disclosed. Risks remain regarding the collaboration's success amidst challenges in biotechnological development.
Read more →-CELU
Aug 3, 2023Letter to shareholders
Celularity's CEO Robert J. Hariri addressed shareholders, highlighting the company's resilience amid industry challenges. The firm secured a $45 million order in the Middle East and continues to advance its cell therapy programs, showing promising early results. Additionally, a commercialization agreement for ocular products was announced, reflecting ongoing strategic growth.
Read more →-CELU
Jul 27, 2023▲ +9.6%on this news
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Celularity Inc. has entered an exclusive U.S. commercialization agreement with Verséa Ophthalmics to distribute its BIOVANCE® and BIOVANCE® 3L Ocular products. These products are designed for treating ocular surface diseases and surgical applications. The partnership aims to leverage Verséa's expertise in eye care to improve patient access to innovative therapies. The global market for corneal epithelial defect management is projected to grow significantly in the coming years.
Read more →-CELU
Jul 27, 2023▲ +9.6%on this newsshared move
Celularity Inc. Announces $3 Million Registered Direct Offering
Celularity Inc. has announced a $3 million registered direct offering of shares and accompanying warrants. The agreement includes the sale of 8,571,428 shares of Class A common stock at a price of $0.35 each, with warrants to purchase an equal number of shares at the same price. The offering is expected to close by July 31, 2023, pending usual closing conditions. Additionally, existing warrants are set to be amended to lower their exercise price, which may provide further investment incentives.
Read more →-CELU
Jul 18, 2023▲ +5.7%on this news
Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies
Celularity Inc. is set to present promising data on its human placental-derived biomaterials at the ICBST23 conference. The studies highlight the therapeutic potential of their products, including Biovance and Interfyl, demonstrating superior biocompatibility and support for cell functions. However, further clinical trials are necessary to validate these findings.
Read more →-CELU
May 31, 2023THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023 All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “for
Celularity Inc. presented its investor update titled 'The Next Evolution in Cellular Medicine' in June 2023, highlighting its forward-looking outlook regarding the development of placental-derived allogeneic cell therapies. The company aims to simplify access to its treatments through a scalable platform that develops therapeutics for various diseases. While Celularity has a strong patent portfolio and ambitious plans, it faces risks inherent to biotechnological development and liquidity challenges. The presentation underscores the need for cautious interpretation of the company's future projections.
Read more →-CELU
Apr 27, 2023Celularity Contact: Paul Graves, Chief Communications Officer Celularity Inc. paul.graves@celularity.com CELULARITY ANNOUNCES CLINICAL DATA ON HUMAN PLACENTAL-DERIVED UNMODIFIED ALLOGENEIC NATURAL KILLER CE
Celularity Inc. announced promising preliminary results from its Phase 1 trial of CYNK-001, an unmodified natural killer cell therapy aimed at treating relapsed refractory acute myeloid leukemia (R/R AML). In the trial, 50% of patients in one cohort achieved significant clinical responses, with an overall positive safety profile noted throughout the study. The findings suggest a pathway toward refining treatment protocols and may inform the development of Celularity's next-generation NK cell therapy, CYNK-301.
Read more →-CELU
Apr 5, 2023▼ -11.5%on this news
Celularity Inc. Announces $6 Million Registered Direct Offering
Celularity Inc. announced a $6 million registered direct offering involving the sale of over 9 million shares of its Class A common stock along with warrants. This move, facilitated through a definitive agreement with a healthcare-focused investor, reflects confidence in Celularity's innovative pipeline of cell therapies and biomaterials. The offering's completion is anticipated around April 10, 2023, pending customary closing conditions, although amended warrants suggest some investor caution. The funds generated will support Celularity's ongoing development of therapeutic programs targeting various diseases.
Read more →-CELU
Mar 17, 2023IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE CELULARITY INC. C.A. No. 2023- - . VERIFIED PETITIONFOR RELIEF PURSUANTTO 8 Del. C. 205 Petitioner Celularity Inc. (“Celularity” or the “Compan
Celularity Inc. has filed a verified petition in the Delaware Court of Chancery seeking validation of its New Certificate of Incorporation and the company's current capital structure. This action arises from concerns regarding the validity of recent amendments following a precedent set by a court decision in Garfield v. Boxed. The company, originally established as a special purpose acquisition company, is focused on developing placental-derived allogenic cell therapies and regenerative products. The court's ruling is crucial as it could impact the company's future operations and stockholder interests.
Read more →-CELU
Jan 26, 2023Celularity Media Contact: Paul Graves SVP, Chief Communications Officer Celularity Inc. paul.graves@celularity.com Celularity Investor Contact: Carlos Ramirez SVP, Investor Relations Celularity Inc. carlos.
Celularity Inc. announced the completion of a strategic review of its 2023 initiatives, highlighting advancements in their commercial biomaterials business and ongoing work in degenerative disease programs. The company is prioritizing its pipeline and making expense reductions to facilitate a ramp-up in biomaterial production. Positive preclinical data from studies on osteoarthritis treatments show potential for significant market opportunities. However, the company is also contemplating workforce reductions and has deprioritized some clinical trials.
Read more →-CELU
Nov 10, 2022▲ +14.5%on this news
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroeso
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancer - Appointed Adrian Kilcoyn
Read more →-CELU
Aug 9, 2022Celularity Reports Second Quarter 2022 Financial Results and Corporate Update - Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update - Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers- - Completed a $30 million priva
Read more →-CELU
Jun 17, 2022THE NEXT EVOLUTION IN CELLULAR MEDICINE June 2022 Page 1 DISCLAIMERS Forward-Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the federal securities laws. Forward-l
DISCLAIMERS Forward-Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding Celularity's expectations, hopes, belief
Read more →-CELU
May 18, 2022Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) Celularity Inc. (Nasdaq: CELU) ( Celularity ), a clinical-stage biotechnology company developing placental-derived off-the-shelf al
Read more →-CELU
May 16, 2022▼ -12.5%on this newsshared move
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate , CYNK-001, in acute myeloid leukemia
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update Florham Park, NJ, May 16, 2022 Celularity Inc. (Nasdaq: CELU) ( Celularity or the Company ), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell
Read more →-CELU
Mar 31, 2022Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute my
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) An
Read more →-CELU
Mar 16, 2022Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified Natural Killer Cell CYNK-001 Acute Myeloid Leukemia(AML) Genetically Modified Natural Killer Cell CYNK-101 +m
Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified Natural Killer Cell CYNK-001 Acute Myeloid Leukemia(AML) Genetically Modified Natural Killer Cell CYNK-101 +mAb Glioblastoma Multiforme (GBM) HER+ Gastric Cancer CAR-T
Read more →-CELU
Feb 15, 2022▲ +8.4%on this news
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers CYNK-101
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers CYNK-101 is an investigational genetically modified NK cell therapy
Read more →-CELU
Jan 18, 2022▼ -8%on this news
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers CYNK-101 i
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers CYNK-101 is an investigational genetically modified natural killer (N
Read more →-CELU
Dec 27, 2021▲ +6.6%on this news
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML FLORHAM PARK, N.J., December 27, 2021 Celularity Inc. (Nasdaq: CELU) ( Celularity ), a clinical-stage biotechnology company developing placental-de
Read more →-CELU
Dec 17, 2021Address 3 Co-dependent variables affecting CYNK-001 potency and persistence in AML: CYNK-001 Cell dose Cyclophosphamide dose [IL-15 and Treg levels] IL-2 Use Determine optimal lymphodepletion regimen that: Enables safe o
CYNK-001 ACUTE MYELOID LEUKEMIA UPDATE December 17, 2021 Exhibit 99.1 Address 3 Co-dependent variables affecting CYNK-001 potency and persistence in AML: CYNK-001 Cell dose Cyclophosphamide dose [IL-15 and Treg levels] IL-2 Use Determine optimal lymphodepletion regimen that: E
Read more →-CELU
Nov 12, 2021Celularity Reports Third Quarter 2021 Financial Results and Corporate Update Florham Park, NJ
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update Florham Park, NJ, - November 12, 2021 - Celularity Inc. (Nasdaq: CELU) ("Celularity"), a clinical-stage biotechnology company developing off-the-shelf, placental-derived allogeneic therapies, today anno
Read more →-CELU
Aug 16, 2021▼ -5.4%on this news
Celularity Reports Second Quarter 2021 Financial Results Secured funding of approximately $138 million through merger and private placement investment in public equity (PIPE) financing Expanded Phase 1 clinical trial to
Reports Second Quarter 2021 Financial Results Park, NJ - August 16, 2021 - Celularity Inc. ("Celularity") (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today reported financial results for the quarter ende
Read more →-CELU
Jul 19, 2021Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol "CELU" on
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol "CELU" on July 19, 2021 Clinical pipeline includes multiple clinical
Read more →-CELU
Jul 1, 2021Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products Arthrex to receive exclusive rights to distribute and commercialize Celularity's placental-derived biomateria
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products Arthrex to receive exclusive rights to distribute and commercialize Celularity's placental-derived biomaterial products for orthopedics and sport medicine in the Unit
Read more →-CELU
Jun 29, 2021Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia No dose limiting toxicity to date with outpatient ad
Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia Park NJ, June 29, 2021 - Celularity Inc. ("Celularity"), a clinical-stage biotechnology company leading the next evolutio
Read more →-CELU
May 14, 2021GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal New York, New York
GX Acquisition Corp. Announces Shareholder Approval of Extension Proposal New York, New York - May 14, 2021 - GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amen
Read more →-CELU
May 10, 2021GX Acquisition Corp. Announces Additional Contributions to Trust Account New York, New York
GX Acquisition Corp. Announces Additional Contributions New York, New York - May 10, 2021 - GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, today reaffirmed its intention to support the proposal to amend GX's amended and resta
Read more →-CELU
May 5, 2021Source: Celularity, Inc.
May 05, 2021 08:00 ET Enters into Multi-Year Strategic Partnership with Palantir Technologies to leverage Palantir's next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities includes equity inv
Read more →-CELU
Apr 16, 2021GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination New York, NY
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination York, NY, April 16, 2021 - On April 14, 2021, GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information regarding a proposal to amend GX's amended and
Read more →-CELU
Mar 18, 2021Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme FLORHAM PARK, N.J.
Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme FLORHAM PARK, N.J., - March 18, 2021 - Celularity Inc. ("Celularity"), a clinical-stage biotechnology company, leading the
Read more →-CELU
Jan 8, 2021Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy 8, 2021 at 8:00 AM EDT PARK, NJ and NEW YORK, NY - January 8, 2021 - Celularity Inc. ("Celularity"), a clinical-stage biotechnology company, leading the next ev
Read more →-CELU
Jul 15, 2019GX Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing
GX Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing July 15, 2019 New York, NY, July 11, 2019 (GLOBE NEWSWIRE) -- GX Acquisition Corp. (NASDAQ: GXGXU) (the "Company") announced today that, commencing July 15, 2019, holders o
Read more →-CELU
May 23, 2019GX ACQUISITION CORP. INDEX TO FINANCIAL STATEMENT PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTIN
GX ACQUISITION CORP. INDEX TO FINANCIAL STATEMENT PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Shareholders and Board of Directors GX Acquisition Corp.
Read more →-CELU
May 20, 2019GX Acquisition Corp. Announces Pricing of $250,000,000 Initial Public Offering New York, NY
Acquisition Corp. Announces Pricing of $250,000,000 Initial Public Offering York, NY, May 20, 2019 (GLOBE NEWSWIRE) -- GX Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 25,000,000 units at $10.00 per unit. The units will be liste
Read more →Competitive Position
How CELU ranks across every disease it competes inCompetitive Position is a premium feature
See how CELU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial